Experimental cell therapy targets aggressive brain tumors
NCT ID NCT04165941
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a new type of cell therapy, made from a patient's own immune cells that are genetically modified to resist chemotherapy, can be safely given alongside standard chemotherapy for newly diagnosed glioblastoma. About 22 adults with this aggressive brain cancer will receive the cell therapy directly into the brain. The main goal is to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- Brain wave decoding aims to shield memory during tumor surgery
- AI reads brain scans to predict tumor survival before surgery